End-of-life research: do we need to build proxy consent into all clinical trial protocols studying the terminal phase? by Sheehan, Caitlin et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
This is a copy of an article published in the Journal of 
Palliative Medicine, and is available online at: 
http://online.liebertpub.com/doi/full/10.1089/jpm.2012.0161 
Please cite this as: Sheehan, C., Agar, M.R. and Currow, D.C., 
2012. End-of-life research: do we need to build proxy 
consent into all clinical trial protocols studying the terminal 
phase? Journal of Palliative Medicine, 15(9), 962. 
DOI: http://dx.doi.org/10.1089/jpm.2012.0161 
© 2012 Mary Ann Liebert, Inc. Paper reproduced here with 
permission from the publisher. 
Letters to the Editor
End-of-Life Research: Do We Need To Build
Proxy Consent into All Clinical Trial Protocols
Studying the Terminal Phase?
Caitlin Sheehan, BMed, FRACP, FAChPM,1,4 Meera Agar, MBBS, M.P.C., FRACP, FAChPM,1–3
and David C. Currow, M.P.H., FRACP1
Dear Editor:
Research into symptoms that occur at the end of life is
paramount for ensuring we provide the best possible care for
patients in the terminal phase, yet obtaining informed consent
from the study participant is not possible at the time these
symptoms occur. Importantly, these questions cannot be an-
swered in any clinical population and defining the net clinical
effect of medications used, for example, for noisy respiratory
secretions is crucial if the quality of care is to be further
improved.
Research into the pharmacological treatment of noisy re-
spiratory secretions at the end of life is facilitated by ad-
vanced consent.1,2 This relies on advanced consent from
potential participants, before they enter the terminal phase,
when there is low likelihood the person may develop the
target symptom. Studies report rates of 4 to 8 consents
required for each randomization. A British study required 58
consented participants, of whom 15 were randomized and
received study medication over the 7-month period.1 The
study aimed to randomize a total of 250 subjects and pre-
dicted 75–100 participants per year. Likewise in an Austra-
lian study, to randomize 10 participants, the investigators
consented 80 people over a 10-month time period.2 A current
phase II feasibility trial of a randomized placebo controlled
trial of glycopyrrolate for the treatment of the same symp-
tom3 to date has screened 250 admissions to an inpatient
palliative care unit in a 6-month period, of which 80 people
were unable to give consent due to reduced capacity. Al-
though there are defined benefits of consent ahead of time,
the ratio of consents to randomization and the exclusion of
those people admitted when they are too unwell to provide
prior consent threatens the feasibility and generalizability of
such research.
Proxy consent may provide the solution to improve the
feasibility of end-of-life research. Proxy consent is sought
from the person, as defined by local legislation, who is re-
sponsible for medical decision making when someone lacks
capacity. In the largest study of the symptom published
to date, proxy consent was the only consent in 80% of the
333 participants.4
Differentmodels exist forwho can approve proxy consent to
be used in clinical trials. In some jurisdictions human research
ethics committees can provide this overview, and in others
there is a centralized specialist agency whose entire function is
to provide oversight for decision making in clinical care and
research for people unable to provide their own consent.
For studies to be adequately powered and to optimize
generalizability, advanced consent is not sufficient, and a
more realistic approach is to ensure that proxy consent is built
into every study design for symptoms in the terminal phase of
a life-limiting illness.
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